spacer
home > ebr > winter 2002 > personal genomes
PUBLICATIONS
European Biopharmaceutical Review

Personal Genomes

Recently, Dr Craig Venter created a stir by announcing that he was, for the princely sum of half a million dollars, providing the opportunity for high net worth individuals (presumably!) to have their whole genome sequenced. In fact, Dr Venter is interested from a scientific standpoint in acquiring comprehensive information about genetic variation in a number of individuals. It is a neat way of funding this endeavour if the individuals are prepared to pay for the activity themselves. But what would they gain for their money? Will useful information be provided or is this just another trophy purchase? Who gets the most out of this unusual contract? The view of some commentators has been that the CD containing their genetic code that these wealthy individuals will receive will have little more than novelty value. They argue that our understanding of the genome is so rudimentary that little interpretative value can be extracted at this stage.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Nick McCooke, Chief Executive Officer of Solexa

Nick McCooke, Chief Executive Officer of Solexa, was formerly President of Seattle-based genomics company Rapigene (now part of Qiagen NV), which under his leadership built one of the world's first fully operational high-throughput genotyping facilities.

From 1991 to 1998, he held a number of general management positions at Innovex (now part of Quintiles) including President of Innovex Japan, with responsibility for setting up a successful business based in Tokyo. Previously Nick worked for the UK biotech company, Celltech, in a number of commercial and general management roles. He holds a BSc and MSc in Engineering and an MBA from the London Business School.

spacer
Nick McCooke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement